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Abstract  
 
Background and Purpose: Shoulder pain is a common complication after stroke which can 
impede participation in rehabilitation and has been associated with poorer outcomes. Evidence 
based treatments for hemiplegic shoulder pain are limited.  Suprascapular nerve block (SSNB) is 
a safe and effective treatment of shoulder pain associated with arthritic shoulder conditions, but 
its usefulness in a stroke population is unclear. 
 
Methods: We undertook a randomised controlled trial assessing the effectiveness of SSNB in a 
population of 64 stroke patients (onset < 1 year) with hemiplegic shoulder pain. The primary 
outcome was pain measured on a visual analogue scale (VAS). Secondary outcomes were 
disability (Modified Rankin Scale, Croft Disability Index) and quality of life (EuroQol Health 
Questionnaire).  All participants were assessed prior to randomisation, and at 1, 4 and 12 weeks 
post intervention. Both groups continued with routine therapy. 
 
Results:  Whilst both intervention and control groups demonstrated reduction in pain score,  
participants who received SSNB consistently demonstrated superior, statistically significant pain 
reduction compared to placebo.  Mean VAS reduction in the SSNB group was over 18mm 
greater than participants receiving placebo injection. The number needed to treat with SSNB to 
reduce one stroke survivor’s pain by 50% at four weeks is 4.  No significant differences in 
function or quality of life were observed.   No adverse events were reported. 
 
Conclusions: Suprascapular nerve block is a safe and effective treatment for patients with 
hemiplegic shoulder pain. 
 
Clinical Trial Registration Information: This trial is registered with the Australian New 
Zealand Clinical Trials Registry (ANZCTR) - ACTRN12609000621213.   
  
Text 
 
Introduction:  
 
Shoulder pain is a distressing complication of hemiplegia
1
 and is one of the four most commonly 
reported medical complications of stroke
2
. The aetiology of hemiplegic shoulder pain is 
multifactorial
3,4
 and contributions have been described from biomechanical changes
1,5
, 
spasticity
6,7 
and central-pain mechanisms
8,9
.   
 
Population based studies suggest that approximately one quarter of stroke survivors develop 
hemiplegic shoulder pain
10,11
, though higher rates of 52-54% have been reported in large studies 
using retrospective
12
, prospective
13
 and literature review
14
 methodologies.   Hemiplegic shoulder 
pain is associated with reduced functional ability
15
, a higher incidence of depression
15
,  
interference with rehabilitation and an increased length of hospitalisation
16
.  
 
Despite the high incidence and significant impact of shoulder pain post stroke, there is little 
robust evidence to inform clinical practice
17,18 
with reviews examining the management of 
hemiplegic shoulder pain concluding that further efforts are required to examine intervention 
options
1,17,18
. 
 
Published systematic reviews have not included information on the use of suprascapular nerve 
block (SSNB) as an intervention type due to the emerging nature of this procedure in stroke 
populations and a lack of robust trials.  Since commencement of this trial, two small trials have 
been published in this field
19,20
.   Comparison of SSNB with intra-articular steroid injection
20
 did 
not demonstrate either treatment to be superior, whilst in a preliminary study
19
 of ten people, 
comparison of SSNB with ultrasound treatment trended toward greater improvement in the 
SSNB group.  Conclusions regarding the efficacy of SSNB are unable to be drawn from these 
studies due to small numbers, absence of power analysis and absence of placebo control.   
 
Suprascapular nerve block has been shown to be a safe
21
 and efficacious treatment for shoulder 
pain associated with rheumatoid arthritis and degenerative shoulder conditions
22,23,24
. It is unclear 
whether the results of these trials can be generalised to people with non-arthritic shoulder pain. 
The objective of our study was to compare the effect of SSNB to placebo on shoulder pain in a 
population of stroke survivors in the first year after stroke.  The secondary objective was to 
examine the effects on function and quality of life. 
 
 
Methods: 
 
The study design is a parallel group, randomised, placebo controlled trial. Sixty four participants 
gave written informed consent and were randomly assigned to an experimental group 
(suprascapular nerve block) or placebo group (normal saline injection).  A protocol paper was 
published at commencement
25
. 
 
 
Setting 
Participants were recruited from acute stroke and rehabilitation wards across Adelaide, South 
Australia between 2009 and 2012. Ethics approval was granted for all sites, including 
Repatriation General Hospital, Flinders Medical Centre, The Queen Elizabeth Hospital, 
Hampstead Rehabilitation Centre, Griffith Rehabilitation Hospital and Calvary Rehabilitation 
Hospital.  Participants were recruited following education sessions and provision brochures to 
each facility.   
 
Participants and Eligibility Criteria 
Participants were required to be aged over 18 years with a diagnosis of acute stroke within the 
previous 12 months, and to report hemiplegic shoulder pain with a minimum VAS  of 30 mm  
(100 mm scale).  Minimum pain score was selected in the clinical context that invasive 
interventions are not routine for mild pain.  Exclusion criteria included significant cognitive 
impairment (Mini-Mental State Examination < 23) or language deficits (inability to follow 2-
stage command, limited English) that might affect the reliability of responses to outcome 
measures scales. Hypersensitivity to injection agents excluded participation.. Following protocol 
publication and trial commencement, authors decided to exclude palliative patients, as it was 
deemed unethicial to knowingly offer placebo during palliation.   
 
Randomisation, Treatment Allocation and Blinding 
A computer generated randomised number sequence  allocated participants to either the 
intervention or the control group.  Randomisation was managed by a Clinical Trials Pharmacist 
external to the study.  Allocation was assigned after baseline assessment. The principal 
investigator (ZA) was responsible for eligibility assessment, consent, baseline assessment and 
injection of all participants.  Where she was involved in treating the participant, consent was 
obtained by another investigator.  All outcome assessments were completed by one 
physiotherapist who was masked to treatment allocation.  Participants and treating staff remained 
masked to allocation.   
 
Interventions 
Participants were randomly assigned to receive either a suprascapular nerve block or a placebo 
subcutaneous normal saline injection.  The principal investigator (ZA) was responsible for 
syringe preparation, and was aware of the allocation as the injection technique and appearance of 
syringe contents varied between groups.  Both groups continued to receive routine therapy   
Syringe size and needle gauge (10ml syringe and a 21 gauge 38mm needle) were consistent 
across both groups. Blinding of participants was maintained by consistent preparation and 
positioning of  all patients, and and all received a 2ml subcutaneous infiltration of 1% lidocaine 
prior to injection. 
 
The experimental group received a suprascapular nerve block injection with 1ml of 40mg/ml 
methylprednisolone and 10ml 0.5% bupivacaine hydrochloride. The technique used for SSNB 
has been used in a prior trial
22
.  Anatomical landmarks were used to determine injection site into 
the supraspinous fossa (please see http://stroke.ahajournals.org). The needle was introduced 
parallel to the scapula blade and the syringe contents slowly injected into the enclosed space of 
the supraspinous fossa.  The placebo group received an injection of 5 ml normal saline infiltrated 
subcutaneously to the same region of the shoulder.  
 
Outcomes  
Participants were assessed prior to randomisation and at 1, 4, and 12 weeks following injection. 
Demographic data collected included age, gender, dominance, duration since stroke, stroke type 
and location.  The primary outcome of pain was measured using a vertical Visual Analogue Scale 
(VAS). This measure involves a 100mm vertical line  anchored with the extremes of subjective 
pain. Self-perceived pain severity is rated and recorded in millimetre readings
26
.  The VAS is 
easy to use, readily reproducible
27
, validated in a stroke population
28
 and a commonly used in 
prior research.  A minimum VAS change of 20mm is reportedly required to achieve clinically 
significant pain reduction for patients with initial pain scores  >60 mm
26
.  Secondary outcomes of 
disability and quality of life were measured using the Modified Rankin Scale
29
, Croft Disability 
Questionnaire
30
, and the EuroQol Health Questionnaire
31
. The Croft Disability Questionnaire 
includes twenty-two questions regarding disability associated with shoulder pain. This validated 
measure was chosen due to applicability in a more dependent population. The minimal level of 
detectable change (90% confidence) is defined as 3 points.  
 
Sample Size and Statistical Analysis 
A prospective sample size calculation, previously described in protocol paper
25
, calculated that a 
sample size of 26 participants per group was required to achieve a statistically and clinically 
significant difference between the two groups (power 80%, alpha 0.05).  Minimally significant 
clinical change in VAS was set at 20mm.  Allowing for an attrition rate of 20% to accommodate 
deaths and withdrawals, we aimed to recruit a total of 66 participants, 33 per group.  
 
Research into the efficacy of SSNB in shoulder pain associated with rheumatoid arthritis
22
 
demonstrated a mean VAS difference of 22.9mm at one week, with the intervention superior to 
placebo. This study was used to assist in the development of the power calculation, with the 
hypothesis that treatment with SSNB would reduce hemiplegic shoulder pain by the minimally 
important clinical change of 20mm when compared to placebo injection. 
 
All data entry was completed by a research assistant masked to allocation.  Data was exported 
into IBM SPSS (version 20) for statistical analyses on an intention to treat basis.  Independent 
samples t-tests, Mann-Whitney U tests and Chi-square test of association were used to compare 
groups at baseline.  Repeated measures were analysed using a generalized linear mixed model 
due to advantage in dealing with missing values (maximum likelihood analysis)
32 
and the robust 
approach to calculation of effect.  Results of primary outcomes are expressed as means with 95% 
confidence intervals.  The level for statistical significance for hypothesis tests was set at 0.05.  
Linear regression analysis was performed to assess potential associations in responding patients.  
EQ-5D weights were derived using the Australian general population algorithm
33
. 
 
 
Results: 
 
Of 129 persons assessed for eligibility, 64 were enrolled and randomised into two groups (Figure 
1).  Reasons for exclusion are tabulated in online supplement (please see 
http://stroke.ahajournals.org). The mean time from stroke onset to trial referral was 12 weeks; 
11(SD 8) weeks for control group and 13(SD 9) weeks for intervention group.  The mean 
difference between scheduled and actual follow up was less than one day for all time points. 
 
Three participants in the control group were lost to follow up. One further control participant was 
not available for follow up at four weeks, but was available at subsequent time points. One 
participant from the control group and three from the intervention group were unable to be 
contacted at 12 weeks. A total of 29 participants in the intervention group and 28 in the control 
group completed the trial with an overall attrition rate of 11%.  
 
The demographic characteristics of participants at baseline were similar across groups (Table 1).  
The groups were well matched on stroke severity (NIHSS), motor weakness of the affected upper 
limb, and pain severity (VAS). Percentages of infarct versus haemorrhage were comparable, and 
Oxfordshire stroke classification demonstrated equivalent numbers of anterior and posterior 
circulation strokes.  Potentially confounding factors such as spasticity and subluxation were also 
similar.  No gender-based differences were detected. 
 
 
Primary Outcomes 
Results for the primary outcome of pain (VAS) are summarised in Table 2 and Figure 2.  Mean 
pain scores at baseline were comparable across the groups (p=0.379).  Pairwise contrasts between 
groups were statistically significant at all follow up time points, with the SSNB group 
consistently demonstrating greater mean VAS reduction when compared to placebo (p=0.02 at 
Week 1, p=0.01 at Week 4, p=0.02 at Week 12).    Linear regression analyses were performed to 
assess associations and predictors of responders.  There were no statistically significant 
associations between any of the variables assessed; namely age, gender, spasticity (Modified 
Ashworth Scale), stroke severity (baseline NIHSS) or disability (Croft Disability Index). 
  
Secondary Outcomes 
There were no differences between groups at any follow up time point in the secondary outcomes 
of disability and quality of life which were assessed with Modified Rankin Scale (mRS), Croft 
Disability Scale and EuroQol Health Questionnaire (EQ-5D).  Both the intervention and control 
groups recorded a mean mRS score of 4(SD 1) at baseline.  The majority of participants in both 
groups had a mRS of 3 or 4 (moderate – moderately severe disability) at all time points.  The 
mean change in Croft Disability Index was non-significant between groups and at each follow up 
time point.  EQ-5D weights for both groups reflected improved health-related quality of life over 
time, independent of effect from group allocation.  
 
No adverse effects were reported.   
 
 
Discussion 
Comparable clinically important variables at baseline reflected successful randomisation.  Whilst 
there was a higher proportion of total anterior circulation strokes (TACS) in the control group, 
the composite of total and partial anterior syndromes (TACS and PACS) was evenly distributed 
(81.3% in control group, 84.4% in intervention group). It is possible that subjective pain report in 
participants with TACS may have been influenced by higher cortical dysfunction, though the 
authors accounted for this in exclusion criteria. Whilst the difference of 4.12mm in baseline VAS 
between groups did not reach clinical or statistical significance, it could indicate a potential 
confounding factor.  The mean time between stroke onset and enrolment was similar between 
groups, in keeping with the typical nadir of hemiplegic shoulder pain at the 2-3 month mark
34
. 
A single SSNB injection provides superior reduction in hemiplegic shoulder pain in comparison 
to placebo injection.  The SSNB group demonstrated a mean VAS reduction of approximately 
37mm, with an 18mm difference between intervention and control groups, maintained at each 
assessment. The definition of a minimal clinically important change on the 100mm VAS has 
been debated; papers report clinical importance from as little as 12mm
35
-15mm
36
, up to 
30mm
37,38
.  In our pre-trial protocol we aimed for a VAS change of 20mm to reach a robust level 
of clinical importance
26
. In order to consider our results in a clinically relevant context, data were 
subsequently reviewed to assess the percentage of responders who achieved criteria for patient 
defined successful
37
 pain reduction of 50% and 30mm. The 4 week time point was taken to be of 
highest clinical interest, given the known pharmacodynamics of the active injection agent.  At 4 
weeks, 78% of all participants receiving SSNB reported any improvement in symptoms, with 
80% of these responders demonstrating > 20mm VAS pain reduction.  The number needed to 
treat with SSNB to achieve a clinically significant pain reduction of 50% in one person was 4 
(95%CI 3-29) at four weeks and 4 at twelve weeks (95%CI 2-25). 
 
The marked placebo response (mean change of 25mm) is expected
39
 in a subjective outcome trial 
utilising a sham injection, and is consistent with other studies of SSNB
22
.  A degradation of this 
effect over follow up might have been expected
22
 and we hypothesize that the maintained 
placebo response over time may reflect the natural history of hemiplegic shoulder pain as 
compared to degenerative shoulder conditions.  
 
Despite significant pain reduction, there was no impact on the secondary outcomes of function 
and quality of life.  .  The self reporting of health-related quality of life following stroke is 
affected by multiple factors, and improvement in a single variable of pain was insufficient to 
improve overall quality of life.  Pain reduction may allow for more intensive therapies which 
could impact future independence. 
 
Suprascapular nerve block is not a new intervention
40
.  There has been an increasing body of 
literature in non-stroke populations, describing the SSNB as a simple, successful and 
reproducible intervention.  As evidenced by results of this trial, the breadth of application of this 
intervention continues to expand.  The suprascapular nerve involves a high proportion of 
sympathetic fibres, and supplies 70% of pain fibres to the shoulder..  The mechanism of initial 
pain reduction is attributed to blocking these sensory fibres
23
 and reducing nociceptive input to 
the central nervous system
20
.  Lack of degradation of treatment effect by 3 months suggests an 
additional potential mechanism in this population.  It has been postulated
22
 that there may be a 
reduction in central sensitisation secondary to diminished nociceptive stimulus as a potential 
effect of SSNB.  This is in keeping with more recent studies which have identified features 
consistent with somatosensory sensitisation in patients with HSP, suggesting both nociceptive 
and neuropathic components
9
 of pain.  
 
 
Strengths and Limitations 
This is the first randomised controlled study to investigate SSNB as a treatment for hemiplegic 
shoulder pain.  We recruited from stroke and rehabilitation settings across the city and believe 
our findings are generalisable to clinical practice.  A single injector and single outcome assessor 
throughout this study reduced the risk of variations in technique and assessments.  In future 
studies, alternatives to the Croft Disability Index could be considered.  In practice, this 
questionnaire did not clearly delineate between disability secondary to hemiplegia and limitations 
secondary to pain.   
 
The major limitation of this trial is that it is a small study with a comparatively short follow up 
period of 3 months.  Estimation of treatment effect may be greater in this current study given the 
influence of a smaller sample size
41
.   Further work is required with larger sample size, with the 
aim of identifying characteristics of clinical responders and clarifying the mechanism of therapy 
effect in this population.  
 
 
Summary / Conclusion: 
Suprascapular nerve block is a safe and effective treatment option for patients with hemiplegic 
shoulder pain in the first year after stroke.  The intervention is easily reproducible in the clinical 
setting, offering a practical and important advance for this patient population. 
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Tables  
 
Table 1. Baseline characteristics of participants with hemiplegic shoulder pain 
Baseline Variable Control (n=32) Intervention (n=32) 
Age in years  
0-65 
66-79 
80+ 
 
16 (50%) 
13 (40.6%) 
3 (9.4%) 
 
15 (46.9%) 
19 (28.1%) 
8 (25%) 
Number (%) male 15 (46.9%) 21 (65.6%) 
Number (%) right hemisphere stroke  21 (65.6%) 23 (71.9%) 
Number (%) right hand dominant 26 (81.3%) 29 (90.6%) 
Duration post stroke in weeks mean (SD) 
NIHSS* mean (SD) 
Total
†
 NIHSS 
Motor score
‡
 affected arm  
11 (8) 
 
8 (4)  
2 (1) 
13 (9) 
 
7 (3)  
2 (1) 
Stroke Type 
Number (%) Infarct  
Number (%) Haemorrhage 
 
29 (90.6%) 
3 (9.4%) 
 
27 (84.4%) 
5 (15.6%) 
Oxfordshire classification
§
 
TACS 
PACS 
LACS 
POCS 
Other 
 
10 (31.3%) 
16 (50.0%) 
4 (12.5%) 
1 (3.1%) 
1 (3.1%) 
 
6 (18.8%) 
21 (65.6%) 
2 (6.3%) 
2 (6.3%) 
1 (3.1%) 
Values are number (%) unless otherwise stated 
*NIHSS = National Institute of Health Stroke Scale 
†
NIHSS total score 5-15 = moderate severity stroke 
‡
NIHSS motor score upper limb of 2 = some effort against gravity, limb cannot get to or be 
maintained at 90° 
§
Oxfordshire Classification: TACS = total anterior circulation syndrome; PACS = partial anterior 
circulation syndrome; LACS = lacunar syndrome; POCS = posterior circulation syndrome 
 
 
 
  
Number with subluxation (%) 
Modified Rankin Scale mean (SD) 
10 (31.3%) 
4 (1) 
10 (31.3%) 
4 (1) 
Croft Disability Q mean (SD) 12 (5) 12 (4) 
Modified Ashworth Scale 
0 
1 
2 
3 
 
16 (50%) 
11 (34.4%) 
5 (15.6%) 
0 (0%) 
 
16 (50%) 
11 (34.4%) 
2 (6.5%) 
2 (6.5%) 
Table 2. VAS pain scores between groups by treatment allocation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time point Control 
Mean (95% CI) 
Intervention 
Mean (95% CI) 
Pairwise  
Contrast  
Control-intervention 
P value 
Baseline 73.03 (66.10-79.99) 68.91 (62.25-75.56) 04.12 0.379 
1 week 47.90 (36.58-59.21) 29.78 (19.29-40.23) 18.12 0.02* 
4 weeks 49.73 (40.62-58.83) 31.69 (21.40-41.97) 18.04 0.01* 
12 weeks 46.20 (34.63-57.78) 28.14 (17.81-38.46) 18.06 0.02* 
* Statisically significant 
Sequential Bonferroni adjusted significance level is 0.05  
Confidence interval bounds are approximate 
Figure 1.  Flow of Participants Through Study 
 
 
 
 
  
Figure 2: VAS pain scores between groups by treatment allocation 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
